Discovery and origins
Thymosin alpha-1 began as one activity among many in thymosin fraction 5, a partially purified calf-thymus extract…
From a crude thymus extract to a synthetic immune drug
Thymosin alpha-1 began as one activity among many in thymosin fraction 5, a partially purified calf-thymus extract that restored immune function in animals stripped of their thymus. Isolating and sequencing the single peptide responsible took years of careful work.
This unit traces that arc: the thymus-extract era, the 1977 sequencing of thymosin alpha-1, the later realization that it is a fragment of prothymosin alpha, and the shift to a chemically synthesized drug that avoids animal-tissue variability.
Key terms
The thymus-extract era
Researchers knew the thymus was essential for immune function but not why. Work on the thymosins was initiated in 1965, and from 1972 Allan Goldstein and colleagues prepared thymosin fraction 5, a standardized calf-thymus extract that restored immune responses in thymus-deprived animals. It clearly contained something active, but that something was a mixture of at least 40 small acidic polypeptides, not a molecule. The crude fraction reached the clinic before any of its components had been identified: the first investigational new drug application for it was granted in 1974.
The fraction-5 work mattered because it made the case that the thymus exports diffusible immune signals rather than merely housing maturing cells. That case set off a hunt to purify the individual peptides responsible, a hunt that eventually separated the alpha and beta thymosins as distinct molecules. It was never fully closed, though: a later review of the individual peptides pulled out of fraction 5 argued that none of them clears the bar for a true thymic hormone.
AdvancedWhy a crude extract was a dead end as a drug
Animal-tissue extracts vary batch to batch in composition and potency, and fraction 5 in particular was never one substance: it held at least forty mostly small acidic polypeptides. That is general pharmaceutical chemistry plus one fact about this extract, and it is enough to make the point. Fraction 5 was a research tool, not a viable pharmaceutical. The path to a usable drug required identifying the single active peptide, determining its exact sequence, and manufacturing it synthetically, which is precisely the arc that produced thymalfasin.